Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DC-ART: the concept

J Edmonds1

  • 1Department of Rheumatology, St. George Hospital, University of New South Wales, Sydney, Australia.

The Journal of Rheumatology. Supplement
|September 1, 1994
PubMed
Summary
This summary is machine-generated.

New antirheumatic drug classifications include Symptom Modifying Antirheumatic Drugs (SMARD) and Disease Controlling Antirheumatic Therapy (DC-ART). DC-ART offers a new framework for rheumatoid arthritis management, though its criteria remain challenging to meet.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy.

Clinical and experimental immunology·2022
Same author

Group exercise for subjects with osteoarthritis of the knee.

The Australian journal of physiotherapy·2014
Same author

Quantitative gait analysis - comparison of rheumatoid arthritic and non-arthritic subjects.

The Australian journal of physiotherapy·2014
Same author

Use of ethanol in the treatment of distal tarsal joint osteoarthritis: 24 cases.

Equine veterinary journal·2011
Same author

CLIMATE: A New Route Toward Limiting Climate Change?

Science (New York, N.Y.)·2007
Same author

Ecological genomics of marine Roseobacters.

Applied and environmental microbiology·2007
Same journal

GRAPPA 2019 Research Recipient Awards Report.

The Journal of rheumatology. Supplement·2021
Same journal

GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual Meeting.

The Journal of rheumatology. Supplement·2021
Same journal

GRAPPA Patient Research Partner Network: Update to the GRAPPA 2020 Annual Meeting.

The Journal of rheumatology. Supplement·2021
Same journal

Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group.

The Journal of rheumatology. Supplement·2021
Same journal

GRAPPA 2020 Update From the Education Committee.

The Journal of rheumatology. Supplement·2021
Same journal

The Role of Ultrasound in Research and Clinical Practice in Psoriatic Arthritis: Highlights From the GRAPPA Ultrasound Workshop.

The Journal of rheumatology. Supplement·2021
See all related articles

Area of Science:

  • Rheumatology
  • Pharmacology
  • Clinical Therapeutics

Background:

  • Rheumatoid arthritis (RA) management has evolved with new therapeutic classifications.
  • The International League of Associations for Rheumatology (ILAR) and WHO have established new guidelines.
  • Distinguishing between symptom relief and disease modification is crucial in RA treatment.

Purpose of the Study:

  • To introduce and define the new classification of antirheumatic therapy.
  • To highlight the significance of Disease Controlling Antirheumatic Therapy (DC-ART) as a novel concept.
  • To discuss the implications and challenges of the DC-ART category in RA management.

Main Methods:

  • Review and ratification of new therapeutic classifications by ILAR and WHO.

Related Experiment Videos

  • Categorization of antirheumatic drugs into Symptom Modifying Antirheumatic Drugs (SMARD) and DC-ART.
  • Conceptual analysis of the DC-ART category and its role in RA treatment objectives.

    • Main Results:

    • Two primary categories of antirheumatic therapy were ratified: SMARD and DC-ART.
    • SMARDs primarily address symptoms and clinical features of inflammatory synovitis.
    • DC-ART aims to alter the disease course of rheumatoid arthritis, representing a new therapeutic concept.

    Conclusions:

    • The introduction of DC-ART provides a new basis for setting rheumatoid arthritis management objectives.
    • Current SMARDs may not meet the stringent criteria for DC-ART.
    • Further research and clinical evaluation are needed to understand the full impact of DC-ART in RA treatment.